#403 ‒ Peptides: separating scientific promise from marketing hype

Peptides represent a diverse class of molecules that require rigorous scientific evaluation rather than blind adoption based on marketing hype. A robust framework for assessing these compounds involves verifying a clear mechanism of action, demanding evidence of meaningful human clinical benefit, and understanding safety, dosing, and pharmacokinetics. Many popular wellness peptides, such as BPC-157, lack peer-reviewed human randomized trials and rely on murky origin stories, placing them in an unsupported category. Conversely, even biologically active peptides like CJC-1295 often fail to translate molecular activity into functional human outcomes. The gray market for these substances functions as a salvage yard for abandoned pharmaceutical research, where the absence of manufacturing controls and clinical oversight creates significant, unquantified risks. Distinguishing between legitimate medical applications and speculative wellness trends is essential for making informed, evidence-based health decisions.